The CD20/αCD20 ‘suicide’ system: novel vectors with improved safety and expression profiles and efficient elimination of CD20-transgenic T cells
Open Access
- 19 January 2006
- journal article
- Published by Springer Nature in Gene Therapy
- Vol. 13 (9) , 789-797
- https://doi.org/10.1038/sj.gt.3302705
Abstract
Adoptive transfer of T lymphocytes is an attractive strategy for many experimental treatment strategies for cancer. Unfortunately, manipulated T cells could be responsible for serious adverse events. Retroviral CD20-transduced T cells may be able to control these unwanted effects. CD20-positive cells are sensitive to rituximab (RTX), a monoclonal antibody specific for CD20. This permits their selective elimination in vivo in case of adverse events. To this end, a system is required that permits efficient and safe transduction of donor T cells and effective elimination of CD20-positive T cells. We constructed different CD20-encoding retroviral vectors and investigated the impact of inclusion of the woodchuck post-transcriptional regulatory element (WPRE) and the chicken hypersensitivity site 4 insulator elements on the levels, homogeneity and stability of CD20 expression. Importantly, inclusion of either WPRE or insulator elements in the retroviral vector resulted in a dramatic improvement in the stability of CD20 expression. The insulator element also led to a much more homogeneous level of CD20 expression. We also show the efficient elimination of the CD20-transgenic T cells via RTX by different effector mechanisms. In conclusion, we have constructed CD20-encoding retroviral vectors with improved efficiency and safety profiles, which can be used as a suicide strategy.Keywords
This publication has 40 references indexed in Scilit:
- Tumor cells escape suicide gene therapy by genetic and epigenetic instabilityBlood, 2004
- From the bench to the bedside: ways to improve rituximab efficacyBlood, 2004
- Characterization of CD20-Transduced T Lymphocytes as an Alternative Suicide Gene Therapy Approach for the Treatment of Graft-Versus-Host DiseaseHuman Gene Therapy, 2004
- Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistanceOncogene, 2003
- LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1Science, 2003
- The mechanisms of action of rituximab in the elimination of tumor cellsSeminars in Oncology, 2003
- Mechanism of Cytotoxicity Induced by Chimeric Mouse Human Monoclonal Antibody IDEC-C2B8 in CD20-Expressing Lymphoma Cell LinesCellular Immunology, 2000
- Genetic Modification of Human T Cells with CD20: A Strategy to Purify and Lyse Transduced Cells with Anti-CD20 AntibodiesHuman Gene Therapy, 2000
- The Chicken β-Globin 5′HS4 Boundary Element Blocks Enhancer-Mediated Suppression of SilencingMolecular and Cellular Biology, 1999
- HSV-TK Gene Transfer into Donor Lymphocytes for Control of Allogeneic Graft-Versus-LeukemiaScience, 1997